Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,521 across all filing types
Latest filing 2022-07-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - "GABAPENTIN CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a new drug product, Gabapentin Capsules, by the National Medical Products Administration of China. It is a short announcement (2558 characters) that informs the market about a regulatory approval and product development milestone. There are no financial statements, no detailed financial analysis, no meeting materials, no voting results, no management changes, no earnings data, and no legal proceedings discussed. The document is not a report but an announcement of a significant corporate event related to product approval. Given the content and length, it fits best into the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-07-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report for movements in securities, specifically detailing movements in issued shares, share options, and other related share capital information for CSPC Pharmaceutical Group Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows the format FF301, which is a regulatory return under the Exchange Listing Rules Chapter 19B. The document does not contain financial statements, earnings data, or management discussion but focuses on share capital movements and confirmations related to securities. It is a regulatory filing reporting share capital and securities movements rather than a financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-04 English
CONNECTED TRANSACTIONS - LEASE AGREEMENTS
Regulatory Filings Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding new lease agreements entered into with connected persons under Chapter 14A of the Hong Kong Listing Rules. It details the terms, parties involved, rental amounts, and accounting implications under HKFRS 16. The document is a regulatory announcement about connected transactions (lease agreements) and their compliance with listing rules, rather than a financial report, earnings release, or management discussion. It is not a full annual or interim report, nor a call transcript or presentation. The content fits the category of a Regulatory Filing (RNS) as it is a formal announcement of connected transactions required by regulatory rules but does not constitute a financial report or other specific filing type.
2022-06-24 English
VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR JMT103 ACCEPTED BY THE NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the acceptance of a biologic license application (BLA) for a new drug by the National Medical Products Administration (NMPA) in China. It provides details about the drug, its clinical studies, and regulatory status. The document is relatively short (3530 characters) and is an announcement of a regulatory milestone rather than a full financial or operational report. It does not contain financial statements, management discussion, or detailed financial data. It is not a report of voting results, nor a call transcript, nor a capital update. It is a regulatory announcement about a product approval process. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-06-22 English
VOLUNTARY ANNOUNCEMENT - "PRAMIPEXOLE DIHYDROCHLORIDE SUSTAINED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a new pharmaceutical product. It is a short announcement (2490 characters) and does not contain financial data, financial statements, or detailed report content. It is not an annual or interim report, earnings release, or any detailed financial or governance report. It is also not a regulatory filing in the sense of compliance or certification, but rather a corporate announcement about product approval. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-06-13 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 May 2022. It details movements in issued shares, share options, and other share capital related information for CSPC Pharmaceutical Group Limited. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital movements and share options, not a financial report or earnings release. It is a regulatory filing related to share capital movements but does not announce a new share issue or capital change per se, nor is it a report of share repurchases. The document is a compliance filing under exchange listing rules, fitting best under Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS). The document length is about 5,097 characters, which is substantive and contains detailed data, but it is not a financial report or earnings release. Therefore, the best classification is Regulatory Filings (RNS).
2022-06-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.